1 / 14

Emerging Antiplatelet Therapies and the Latest Clinical Trials

Ongoing Trials Evaluating Novel Antiplatelet Drugs or Strategies in ACS and PCI. CURRENT (dosing)TRITON (new ADP)PLATO (new ADP)CHAMPION (IV ADP)ERASE (IV to po ADP)EARLY ACS (IIb/IIIa timing)TRACER and 2P (TRA). Study Design. Clopidogrel High-Dose GroupClopidogrel 600 mg loading dose Day 1 f

deliz
Télécharger la présentation

Emerging Antiplatelet Therapies and the Latest Clinical Trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    2. Ongoing Trials Evaluating Novel Antiplatelet Drugs or Strategies in ACS and PCI CURRENT (dosing) TRITON (new ADP) PLATO (new ADP) CHAMPION (IV ADP) ERASE (IV to po ADP) EARLY ACS (IIb/IIIa timing) TRACER and 2P (TRA)

    3. Study Design CURRENT/OASIS-7 is a Phase III, multinational, multicenter, randomized, factorial design, parallel-group study comparing two regimens of clopidogrel (high vs. standard dose) in a double-blind fashion and two regimens of acetylsalicylic acid (high vs. low dose) in an open-label fashion in patients with non-ST-segment elevation acute coronary syndrome managed with an early invasive strategy with intent for percutaneous coronary intervention as early as possible within 24 hours. Each patient will be treated and followed for 30 days.CURRENT/OASIS-7 is a Phase III, multinational, multicenter, randomized, factorial design, parallel-group study comparing two regimens of clopidogrel (high vs. standard dose) in a double-blind fashion and two regimens of acetylsalicylic acid (high vs. low dose) in an open-label fashion in patients with non-ST-segment elevation acute coronary syndrome managed with an early invasive strategy with intent for percutaneous coronary intervention as early as possible within 24 hours. Each patient will be treated and followed for 30 days.

    4. Study Design To answer this question, we are currently recruiting up to 850 sites for participation in a global phase 3 trial of prasugrel vs. clopidogrel in patients with acute coronary syndromes with planned PCI, called TRITON-TIMI 38. This trial will enroll 13,000 patients across the ACS spectrum. Patients will be randomized to either prasugrel or standard doses of clopidogrel. Patients will be followed on mantenance therapy for a median of 12 months. The primary endpoint will be the composite of cardiovascular death, MI and stroke. Important secondary endpoints include bleeding, recurrent ischemia and urgent target vessel revascularization. Thank you for your attention. To answer this question, we are currently recruiting up to 850 sites for participation in a global phase 3 trial of prasugrel vs. clopidogrel in patients with acute coronary syndromes with planned PCI, called TRITON-TIMI 38. This trial will enroll 13,000 patients across the ACS spectrum. Patients will be randomized to either prasugrel or standard doses of clopidogrel. Patients will be followed on mantenance therapy for a median of 12 months. The primary endpoint will be the composite of cardiovascular death, MI and stroke. Important secondary endpoints include bleeding, recurrent ischemia and urgent target vessel revascularization. Thank you for your attention.

    6. Cangrelor Phase III RCTs

    7. ERASE-MI: Early Rapid ReversAl of Platelet ThromboSis with Intravenous PRT060128 Before PCI to Optimize REperfusion in Acute MI

    8. Study Design

    9. Platelet Receptors

    12. PCI Cohort

    14. While antiplatelet therapies are the cornerstone of CAD care, there are many unresolved questions and opportunities for improving patient care/outcomes. Current and ongoing trials will enroll >90,000 patients over the next few years in attempts to test new strategies and agents. Global collaboration and participation in RCTs is critical to advancing patient care. Emerging Antiplatelet Therapies/Strategies and Ongoing RCTs: Conclusions

More Related